Industry

FDA Approves Roche’s Enspryng, a Subcutaneous At-Home Treatment for Thyroid Eye Disease

Vision Monday12h ago1 min read

BASEL, Switzerland—Pharmaceutical giant Roche (SIX: RO, ROP; OTCQX: RHHBY) has announced that Enspryng (satralizumab), an at-home subcutaneous treatment for adults with thyroid eye disease (TED), has received U.S. Food and Drug Administration (FDA) approval. The nod was based on phase 3 studies that demonstrated what the company said was a significant reduction in eye bulging and improvement in diplopia, with a favorable safety profile. A rare autoimmune disease, TED is said to affect 155 out of every 100,000 people in the U.S. and can lead to vision-threatening complications if left untreated.

Read full article on Vision Monday

AI Summary

Quick Take

The FDA has approved Roche’s Enspryng (satralizumab) as the first subcutaneous, at-home treatment for adults with thyroid eye disease (TED). Phase 3 clinical data demonstrated that the drug significantly reduces eye bulging and improves diplopia, providing a new self-administered option for a condition that affects approximately 155 per 100,000 people in the U.S.

Why It Matters

The approval of Enspryng represents a significant shift in the TED treatment landscape, which has previously been dominated by intravenous infusion therapies like Tepezza. By allowing for subcutaneous at-home administration, this therapy reduces the burden on both patients and clinical infrastructure, potentially improving long-term adherence. For eye care providers, this adds a critical tool to the armamentarium for managing active-phase TED, which can lead to permanent vision loss and significant disfigurement if not addressed early.

Key Findings

Phase 3 clinical trials showed a significant reduction in proptosis (eye bulging) among adult patients.
Treatment with satralizumab resulted in clinically meaningful improvements in diplopia (double vision).
The drug demonstrated a favorable safety profile consistent with its use in other autoimmune indications.
Enspryng is administered via subcutaneous injection, making it the first TED treatment designed for at-home use.

Key Details

Manufacturer: Roche
Drug Name: Enspryng (satralizumab)
Indication: Thyroid Eye Disease (TED) in adults
Administration: Subcutaneous injection
U.S. Prevalence: Approximately 155 cases per 100,000 people

Study Snapshot

Design

Phase 3 clinical studies

Population

Adults with thyroid eye disease (TED)

Practice Implications

Clinicians should consider Enspryng for adult TED patients who prefer at-home management or those for whom regular clinic-based infusions are a logistical barrier. While the delivery method changes, the clinical goals remain the same: monitoring for reductions in proptosis and diplopia while ensuring patients are properly trained on subcutaneous injection techniques.

Who's Affected

OphthalmologistsOculoplastic SurgeonsOptometristsEndocrinologistsPractice Owners

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.